Future cardiology最新文献_第6页

Aficamten in the treatment of obstructive hypertrophic cardiomyopathy. 阿非曲坦治疗梗阻性肥厚性心肌病。

IF 1.6

Future cardiology Pub Date : 2025-07-01 Epub Date: 2025-06-18 DOI: 10.1080/14796678.2025.2521183

Danish Saleh, Maeve Eskandari, Lubna Choudhury

引用次数: 0

Pediatric partial heart xenotransplantation as an early use case of xenograft tissue. 儿童部分心脏异种移植作为异种移植组织的早期应用案例。

IF 1.6

Future cardiology Pub Date : 2025-07-01 Epub Date: 2025-06-24 DOI: 10.1080/14796678.2025.2521993

Eli J Contorno, Herra Javed, Brian Reemtsen, T Konrad Rajab

{"title":"Pediatric partial heart xenotransplantation as an early use case of xenograft tissue.","authors":"Eli J Contorno, Herra Javed, Brian Reemtsen, T Konrad Rajab","doi":"10.1080/14796678.2025.2521993","DOIUrl":"10.1080/14796678.2025.2521993","url":null,"abstract":"Xenotransplantation is a promising advancement in the field of transplantation that could eliminate deaths on the waitlist and provide an unlimited supply of on-demand organs for those in need of this life-saving therapy. The results of preclinical studies in orthotopic heart xenotransplantation have shown that non-human primate models can consistently survive 9 months post-transplant. However, early clinical results in orthotopic heart xenotransplantation have been subpar compared to traditional orthotopic heart transplantation as the longest surviving patient survived for 60 days with a complicated postoperative course. Partial heart xenotransplantation could serve as an earlier clinical use case of xenotransplantation products due to the many advantages of the neonate and infant population for xenotransplantation as well as the unique immunogenicity of heart valves which is significantly lower than that of whole hearts. The adoption of partial heart xenotransplantation would allow more children to realize the benefits of a valve that tolerates somatic growth without the need for serial reoperation.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"725-730"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12263124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic review of the use of oral anticoagulants in patients with peripheral arterial disease. 外周动脉疾病患者口服抗凝剂应用的系统综述。

IF 1.6

Future cardiology Pub Date : 2025-07-01 Epub Date: 2025-06-24 DOI: 10.1080/14796678.2025.2522587

Syed Mohammad Naqvi, Syed Yaseen Naqvi, Hashim Talib Hashim, Ali Shabu, Khayyam Akbar, Aous Hani Nief, Wael Tawfick

{"title":"Systematic review of the use of oral anticoagulants in patients with peripheral arterial disease.","authors":"Syed Mohammad Naqvi, Syed Yaseen Naqvi, Hashim Talib Hashim, Ali Shabu, Khayyam Akbar, Aous Hani Nief, Wael Tawfick","doi":"10.1080/14796678.2025.2522587","DOIUrl":"10.1080/14796678.2025.2522587","url":null,"abstract":"Background: Peripheral arterial disease (PAD) is a condition whereby the peripheral arteries of the body, and particularly the lower limbs, experience atherosclerosis resulting in narrowing of the peripheral arteries. This largely preventable condition is a major cause of cardiovascular morbidity and mortality, affecting over 230 million people worldwide.Methodology: We conducted a systematic search for randomized control trials on four databases: Medline, CINAHL, PubMed, and Embase. We compared the outcomes of anticoagulation therapy with standard care following PRISMA standards.Results: 10,051 studies were identified, and through titles and abstract screening followed by full text screening, five studies involving 14,463 individuals were included. One study compared rivaroxaban with dose adjusted warfarin. Two studies compared a combination of rivaroxaban and low dose aspirin with antiplatelet therapy. These three demonstrated a reduction in major adverse cardiovascular events (MACE) and Major adverse limb events (MALE) when combined with Aspirin. However, they noted increased bleeding risk.Conclusion: Newer-generation direct oral anticoagulants in combination with antiplatelet therapy, may improve cardiovascular outcomes and reduce limb-related complications in patients with PAD. Further randomized controlled trials (RCTs) are needed to determine optimal dosing before guideline implementation.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"711-723"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stenting strategy and imaging use in left main percutaneous coronary intervention: insights from a 15-year registry. 左主干经皮冠状动脉介入治疗支架置入策略和影像学应用：来自15年登记的见解。

IF 1.6

Future cardiology Pub Date : 2025-07-01 Epub Date: 2025-06-06 DOI: 10.1080/14796678.2025.2511416

Judit Andreka, Fazila-Tun-Nesa Malik, Mariam Khandaker, Kalim Uddin, Abdul Kayum, Anass Maaroufi, Dan Prunea, Zoltan Ruzsa, Gabor G Toth

{"title":"Stenting strategy and imaging use in left main percutaneous coronary intervention: insights from a 15-year registry.","authors":"Judit Andreka, Fazila-Tun-Nesa Malik, Mariam Khandaker, Kalim Uddin, Abdul Kayum, Anass Maaroufi, Dan Prunea, Zoltan Ruzsa, Gabor G Toth","doi":"10.1080/14796678.2025.2511416","DOIUrl":"10.1080/14796678.2025.2511416","url":null,"abstract":"Background: Left main (LM) percutaneous coronary intervention (PCI) remains a major interventional challenge, with outcomes influenced by various patient- and procedure-related factors.Objectives: To analyze procedural characteristics and outcomes of patients who underwent LM PCI over a 15-year period in a single center.Methods: We retrospectively analyzed data from all consecutive patients who underwent LM PCI between 2006 and 2022. Procedural details, with a focus on stenting technique, were collected. Primary outcome was all-cause mortality at 1 year.Results: In total 3494 patients were included. The majority (67%) presented with chronic coronary syndrome. Seventy-seven percent of all patients (n = 2690) underwent PCI by single stent (SS) strategy and 23% (n = 804) by double stent (DS) strategy. One-year mortality was significantly lower in SS cases compared to DS (3.5% vs. 5.1%, HR 0.64, 95% CI 0.43-0.96). Intravascular imaging was used in 17% of the cases but showed no significant difference in one-year mortality compared to angio-guided PCI (4.8% vs. 3.7%; HR 1.11, 95% CI 0.71-1.73).Conclusions: In real-world LM PCI practice, patients for whom a provisional single-stent strategy was feasible had better outcomes than those requiring a double-stent approach.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"693-700"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perceptions of high-sensitivity C-reactive protein testing (hsCRP) in atherosclerotic cardiovascular disease: a US survey on cardiologists and nephrologists. 对动脉粥样硬化性心血管疾病的高灵敏度c反应蛋白检测（hsCRP）的看法：一项美国心脏病学家和肾病学家的调查

IF 1.6

Future cardiology Pub Date : 2025-07-01 Epub Date: 2025-06-03 DOI: 10.1080/14796678.2025.2514349

Lei Lv, Ty J Gluckman, Matthew Strum, Jigar Rajpura

{"title":"Perceptions of high-sensitivity C-reactive protein testing (hsCRP) in atherosclerotic cardiovascular disease: a US survey on cardiologists and nephrologists.","authors":"Lei Lv, Ty J Gluckman, Matthew Strum, Jigar Rajpura","doi":"10.1080/14796678.2025.2514349","DOIUrl":"10.1080/14796678.2025.2514349","url":null,"abstract":"Introduction: High-sensitivity C-reactive protein (hsCRP) is a biomarker of systemic inflammation (SI) and its elevated level is considered a risk-enhancing factor for cardiovascular disease in primary prevention. This study aimed to understand opinions of US clinicians using hsCRP testing in the management of patients with atherosclerotic cardiovascular disease (ASCVD) with or without chronic kidney disease (CKD).Materials & methods: Clinicians who ordered hsCRP testing with evaluation of patient-level data were surveyed, between June 2023-August 2023. Endpoints included self-identified drivers and barriers to hsCRP testing and assessment of posttest actions following SI recognition.Results: Common factors perceived to prevent hsCRP testing were a lack of evidence showing improvements in patient cardiovascular outcomes after addressing SI in ASCVD and CKD (50%), and lack of proven efficacy of hsCRP testing (33%). Barriers to hsCRP testing included cost, insurance coverage and patient refusal. The most common reason for not considering SI in clinical decision-making was that it would not affect management of ASCVD. After the first hsCRP testing, an average reduction of hsCRP level is observed, but not lower than 2 mg/L.Conclusions: In this limited study sample, perceived limitations of hsCRP testing included insufficient evidence of improved cardiovascular outcomes in patients with ASCVD.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"701-710"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term safety and effectiveness of evinacumab in people with homozygous familial hypercholesterolemia: a plain language summary. evinacumab在纯合子家族性高胆固醇血症患者中的长期安全性和有效性：简单的语言总结

IF 1.6

Future cardiology Pub Date : 2025-07-01 Epub Date: 2025-06-23 DOI: 10.1080/14796678.2025.2513805

Daniel Gaudet, Susanne Greber-Platzer, Laurens F Reeskamp, Gabriella Iannuzzo, Robert S Rosenson, Samir Saheb, Claudia Stefanutti, Erik Stroes, Albert Wiegman, Traci Turner, Shazia Ali, Poulabi Banerjee, Jennifer McGinniss, Alpana Waldron, Richard T George, Xue-Qiao Zhao, Robert Pordy, Eric Bruckert, Frederick J Raal

引用次数: 0

The importance of post-dilatation during PCI: current evidence and future directions. PCI术后扩张的重要性：目前的证据和未来的方向。

IF 1.6

Future cardiology Pub Date : 2025-06-27 DOI: 10.1080/14796678.2025.2526270

Konrad A J van Beek, Koen Teeuwen, Pim A Tonino